Mirxes Email Format

Biotechnology ResearchCentral Region, Singapore51-200 Employees

Mirxes is a Singapore-based biotechnology company focused on early, actionable, and personalized diagnoses across the care continuum. Its flagship GASTROClear is a blood-based test for early gastric cancer detection, able to identify roughly 90% of Stage I and II cancers. The organization operates with an Asia-centered approach, conducting research, development, manufacturing, and clinical diagnostics in Singapore, the USA, Japan, and China, supported by worldwide sales networks.

Founded in 2014 as a spin-off from A*STAR’s Bioprocessing Technology Institute to commercialize microRNA detection technologies, Mirxes has since expanded its cancer-detection portfolio and aims to address broader clinical needs in cardiovascular, metabolic, and infectious diseases. In a recent development, the company announced the launch of at-home screening kits FITRapid and HELICORapid in Thailand following regulatory approvals in late 2025, signaling broader access to diagnostics.

Get verified Mirxes emails free

Company overview Employee directory